DGS Capital Management LLC Makes New $276,000 Investment in Exelixis, Inc. (NASDAQ:EXEL)

DGS Capital Management LLC acquired a new stake in Exelixis, Inc. (NASDAQ:EXEL) during the 4th quarter, Holdings Channel.com reports. The firm acquired 8,301 shares of the biotechnology company’s stock, valued at approximately $276,000.

Other large investors have also made changes to their positions in the company. USA Financial Formulas purchased a new position in Exelixis in the 4th quarter valued at about $32,000. V Square Quantitative Management LLC purchased a new position in shares of Exelixis during the third quarter valued at approximately $30,000. UMB Bank n.a. lifted its stake in shares of Exelixis by 68.4% during the fourth quarter. UMB Bank n.a. now owns 1,361 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 553 shares during the period. Brooklyn Investment Group acquired a new stake in Exelixis during the third quarter worth approximately $42,000. Finally, MassMutual Private Wealth & Trust FSB grew its stake in Exelixis by 18.1% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,890 shares of the biotechnology company’s stock worth $63,000 after acquiring an additional 290 shares during the period. Institutional investors and hedge funds own 85.27% of the company’s stock.

Exelixis Price Performance

Shares of NASDAQ EXEL opened at $32.38 on Friday. Exelixis, Inc. has a 1-year low of $20.01 and a 1-year high of $37.59. The company has a market capitalization of $9.25 billion, a price-to-earnings ratio of 20.76, a PEG ratio of 0.72 and a beta of 0.53. The business has a 50-day moving average of $34.87 and a 200-day moving average of $29.77.

Exelixis (NASDAQ:EXEL) last announced its earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share for the quarter, beating the consensus estimate of $0.36 by $0.04. Exelixis had a net margin of 22.43% and a return on equity of 20.99%. The business had revenue of $539.50 million during the quarter, compared to the consensus estimate of $490.31 million. During the same period in the prior year, the firm earned $0.10 earnings per share. The business’s quarterly revenue was up 14.3% compared to the same quarter last year. Research analysts expect that Exelixis, Inc. will post 1.74 EPS for the current fiscal year.

Insider Transactions at Exelixis

In other Exelixis news, EVP Jeffrey Hessekiel sold 25,000 shares of Exelixis stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $28.39, for a total transaction of $709,750.00. Following the sale, the executive vice president now directly owns 580,325 shares in the company, valued at $16,475,426.75. The trade was a 4.13 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Patrick J. Haley sold 41,588 shares of the stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $34.36, for a total value of $1,428,963.68. Following the transaction, the executive vice president now owns 288,665 shares of the company’s stock, valued at approximately $9,918,529.40. This trade represents a 12.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 314,736 shares of company stock valued at $10,849,110. 2.85% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several research firms have recently issued reports on EXEL. BMO Capital Markets cut Exelixis from an “outperform” rating to a “market perform” rating and raised their price objective for the stock from $36.00 to $40.00 in a report on Friday, December 20th. Morgan Stanley raised their price target on Exelixis from $26.00 to $28.00 and gave the stock an “equal weight” rating in a research note on Friday, October 11th. Stifel Nicolaus upped their price objective on shares of Exelixis from $26.00 to $30.00 and gave the company a “hold” rating in a research note on Wednesday, October 16th. Royal Bank of Canada reissued an “outperform” rating and issued a $34.00 target price on shares of Exelixis in a research report on Wednesday, October 30th. Finally, Piper Sandler upped their price target on shares of Exelixis from $36.00 to $37.00 and gave the stock an “overweight” rating in a research report on Monday, January 13th. One analyst has rated the stock with a sell rating, eight have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $35.00.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.